Clinical Study Failures Vary Widely by Phase of Study and Therapeutic Class, According to the Tufts Center for the Study of Drug Development
While lack of commercial viability is the leading cause of Phase I failures for new drug candidates, efficacy issues dominate as the reason for Phase II failures, according to a new analysis from the Tufts Center for the Study of Drug Development.
While lack of commercial viability is the leading cause of Phase I failures for new drug candidates, efficacy issues dominate as the reason for Phase II failures, according to a new analysis from the Tufts Center for the Study of Drug Development.
Based on a study of products that entered clinical development from 2000 through 2009, Tufts CSDD found that commercial reasons accounted for 40.9% of all Phase I failures, but only 27.3% of Phase II failures. Efficacy issues explained 50.9% of Phase II failures.
Clinical study failures also vary widely by therapeutic class of drugs being investigated, the analysis showed.
"It is in the interest of drug developers to have new products fail earlier, rather than later, in development, as earlier terminations avoid the costs of larger, more complex studies," said Joseph A. DiMasi, Tufts CSDD director of economic analysis, the principal investigator on the study.
He added, "While there is natural resistance to give up on a compound too early, the need to reduce costs and boost productivity is leading developers to establish new approaches to R&D, including the increased use of biomarkers and novel clinical trial designs, with the goal of terminating candidates as early as possible."
The analysis, reported in the September/October Tufts CSDD Impact Report, released today, also found that:
- Safety issues accounted for nearly twice as many Phase III failures as did commercial reasons: 29.5% vs. 15.9%.
- Efficacy issues accounted for 54.3% of respiratory drug failures and 48.3% of drug candidates to treat central nervous system diseases.
- Cardiovascular drugs experienced the highest prevalence of commercial failures (46.7%) among all classes of compounds analyzed.
The study, based on investigational drugs in the pipelines of the top 50 firms in terms of pharmaceutical sales, examined the development histories of 812 compounds, which had 1,369 failed indications, and established reasons for failure by clinical phase for 410 of these compounds and 659 indications.
Improving Relationships and Diversifying the Site Selection Process
April 17th 2025In this episode of the Applied Clinical Trials Podcast, Liz Beatty, co-founder and chief strategy officer, Inato, discusses a number of topics around site engagement including community-based sites, the role of technology in improving site/sponsor relationships, how increased operational costs are impacting the industry, and more.
Behind the Buzz: Why Clinical Research Leaders Flock to SCOPE Summit
February 7th 2025In this episode, we meet with Micah Lieberman, Executive Conference Director for SCOPE Summit (Summit for Clinical Ops Executives) at Cambridge Innovation Institute. We will dive deep into the critical role of collaboration within the clinical research ecosystem. How do we bring together diverse stakeholders—sponsors, CROs, clinical trial tech innovators, suppliers, patients, sites, advocacy organizations, investors, and non-profits—to share best practices in trial design, program planning, innovation, and clinical operations? We’ll explore why it’s vital for thought leaders to step beyond their own organizations and learn from others, exchanging ideas that drive advancements in clinical research. Additionally, we’ll discuss the pivotal role of scientific conferences like SCOPE Summit in fostering these essential connections and collaborations, helping shape the future of clinical trials. Join us as we uncover how collective wisdom and cross-industry partnerships are transforming the landscape of clinical research.
FDA-Approved Gene Therapy Beqvez Shows Sustained Efficacy, Safety in Long-Term Hemophilia B Trial
April 17th 2025Beqvez (fidanacogene elaparvovec), an FDA-approved one-time gene therapy for hemophilia B, demonstrated sustained factor IX expression, low bleeding rates, and a favorable safety profile over long-term follow-up.
